Literature DB >> 28165318

An Evaluation Approach for the Performance of Dosing Regimens in Attention-Deficit/Hyperactivity Disorder Treatment.

Guillaume Bonnefois1, Philippe Robaey2,3,4, Olivier Barrière5, Jun Li1,6, Fahima Nekka1,6.   

Abstract

OBJECTIVE: Stimulant medications, with methylphenidate as the main agent, are the most prescribed for the treatment of attention-deficit/hyperactivity disorder. Nevertheless, real challenges still remain for clinicians concerned with adaptation of the therapeutic regimens, in terms of doses and timing, to children's daily activities. The aim of this study was to optimize short-acting methylphenidate regimens according to specific children's needs by evaluating the performance of a particular regimen through a web-based application.
METHODS: In this article, accounting for day-to-day children's activities and using up-to-date pharmacokinetic knowledge of methylphenidate, we propose a computational approach for the identification of the most suitable dosing regimens of immediate-release formulations of methylphenidate based on constraints on drug concentration and time frame of activities, defined through therapeutic boxes. To assess the performance of these regimens, time- and concentration-based therapeutic indicators, as well as a roller coaster effect, are proposed.
RESULTS: A web-based interface that can serve as an educational tool for clinicians and patients has been developed based on the proposed approach for the evaluation of dosing regimens. Comparison of those optimal regimens identified by our method with the well-accepted regimens defined in the NIMH Collaborative Multisite Multimodal Treatment study of Children with attention-deficit/hyperactivity disorder indicates that there is still room for improvement in the current practice especially for the last dose administration to avoid side effects such as sleep disturbance.
CONCLUSION: The developed approach and its associated web-based interface provide an efficient way to evaluate and adapt the methylphenidate regimens to children's daily activities. In addition, this approach could be used as proof of concept to further implement combination of short- and long-acting methylphenidate.

Entities:  

Keywords:  dose adaptation; eHealth; methylphenidate; population pharmacokinetics; precision medicine; web-based application

Mesh:

Substances:

Year:  2017        PMID: 28165318      PMCID: PMC5460958          DOI: 10.1089/cap.2016.0108

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  30 in total

1.  The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations.

Authors:  Nathanel Zelnik; Ruth Terkel-Dawer
Journal:  Atten Defic Hyperact Disord       Date:  2015-04-03

2.  Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.

Authors:  Sharon B Wigal; Suneel Gupta; Erica Heverin; H Lynn Starr
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-06       Impact factor: 2.576

3.  Medication treatment strategies in the MTA Study: relevance to clinicians and researchers.

Authors:  L L Greenhill; H B Abikoff; L E Arnold; D P Cantwell; C K Conners; G Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; J S March; J Newcorn; W E Pelham; J B Severe; J M Swanson; B Vitiello; K Wells
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-10       Impact factor: 8.829

4.  Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.

Authors:  Ozgur Yorbik; Caner Mutlu; Selma Ozilhan; Gul Eryilmaz; Nuket Isiten; Serdar Alparslan; Esra Saglam
Journal:  Ther Drug Monit       Date:  2015-06       Impact factor: 3.681

5.  Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.

Authors:  L L Greenhill; J M Swanson; B Vitiello; M Davies; W Clevenger; M Wu; L E Arnold; H B Abikoff; O G Bukstein; C K Conners; G R Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; H C Kraemer; J S March; J H Newcorn; J B Severe; K Wells; T Wigal
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

6.  Relationship between subjective effects of cocaine and dopamine transporter occupancy.

Authors:  N D Volkow; G J Wang; M W Fischman; R W Foltin; J S Fowler; N N Abumrad; S Vitkun; J Logan; S J Gatley; N Pappas; R Hitzemann; C E Shea
Journal:  Nature       Date:  1997-04-24       Impact factor: 49.962

Review 7.  Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?

Authors:  John S Markowitz; Kennerly S Patrick
Journal:  J Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.153

8.  Methylphenidate effects on neural activity during response inhibition in healthy humans.

Authors:  Anna Costa; Michael Riedel; Oliver Pogarell; Frank Menzel-Zelnitschek; Markus Schwarz; Maximilian Reiser; Hans-Jürgen Möller; Katya Rubia; Thomas Meindl; Ulrich Ettinger
Journal:  Cereb Cortex       Date:  2012-05-10       Impact factor: 5.357

Review 9.  Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis.

Authors:  Viktória Simon; Pál Czobor; Sára Bálint; Agnes Mészáros; István Bitter
Journal:  Br J Psychiatry       Date:  2009-03       Impact factor: 9.319

10.  A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Authors:  Ann Childress; Jeffrey Newcorn; Jeffrey G Stark; Russ McMahen; Mark Tengler; Carolyn Sikes
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-05-26       Impact factor: 2.576

View more
  1 in total

1.  The Decrease in Human Endogenous Retrovirus-H Activity Runs in Parallel with Improvement in ADHD Symptoms in Patients Undergoing Methylphenidate Therapy.

Authors:  Chiara Cipriani; Maria Bernanda Pitzianti; Claudia Matteucci; Elisa D'Agati; Martino Tony Miele; Valentina Rapaccini; Sandro Grelli; Paolo Curatolo; Paola Sinibaldi-Vallebona; Augusto Pasini; Emanuela Balestrieri
Journal:  Int J Mol Sci       Date:  2018-10-23       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.